Carlsbad, California (March 2, 2023) – RCE Technologies, Inc. has just announced a major addition to the clinical team: the highly acclaimed Ronald P. Karlsberg, MD, FACC. As a Clinical Professor of Medicine at the prestigious Smidt Heart Institute at Cedars-Sinai and the David Geffen School of Medicine at UCLA, Dr. Karlsberg has established himself as a leader in clinical cardiology and is widely respected for his expertise in Preventive and Interventional Cardiology. He also serves as the President and one of the Founders of the Cardiovascular Research Foundation.
“Dr. Karlsberg is a clinical leader and physician executive. This is an exciting opportunity for RCE, and I’m thrilled he will join RCE at the cutting edge of transdermal biomarker research that could potentially transform clinical management of cardiovascular disease,” said RCE’s founder and CEO Atandra Burman.
Dr. Karlsberg has received hundreds of research grants, has published numerous peer reviewed papers and book chapters, and is a frequent invited speaker at local, national, and international meetings. With his early pioneering research in myocardial enzymes, myocardial infarction and particular interest in the integration of biomarkers in Preventive, Interventional Cardiology, and Advanced Imaging we are honored to have his expertise join the clinical team and accelerate clinical feasibility efforts for our technology.
In Dr. Karlsberg’s own words, “I look forward to helping RCE advance clinical feasibility of its transdermal optical technology by conducting research in collaboration with top clinical institutions and finding the optimal integration of this technology in clinical practice. ‘Point of care’ determination of biomarkers has the potential to be transformational for the care of the cardiac patient and will save lives.”
About RCE:
RCE.ai, an innovative artificial intelligence (AI) based medical technology company launched in Carlsbad, Calif., in 2018, is dedicated to early heart attack detection. The company has revolutionized the monitoring of cardiac injury by introducing Infrasensor™, a non-invasive infrared-based wearable device. RCE’s proprietary transdermal approach, enhanced with deep learning techniques, analyzes and associates unique optical signatures with cardiac conditions in real-time. This AI-coupled transdermal approach enables the potential application of RCE’s technology in various emergency care settings and remote monitoring applications. Presently, RCE is engaged in clinical studies to optimize the Infrasensor for clinical use. Through ongoing clinical studies, the company hopes to soon secure FDA approval for its technology, opening the door to making it available for sale in the United States.